Ventolin

Evidence outlook · registrational

Asthma: registrational readout pending

Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

NCT06644924: The study randomized 118 participants to treatment sequences and used quadruple masking for PT007 and placebo, while Ventolin was open label; the primary outcome was the surrogate lung-function measure FEV1 AUC. Because the registry has no posted results, whether the primary endpoint was met is unknown, supporting a moderate evidence grade rather than a strong one.